KalVista Pharmaceuticals, Inc. $KALV Shares Bought by Woodline Partners LP

Key Points

• Woodline Partners LP increased its stake in KalVista Pharmaceuticals by 25.5% in Q1, owning 1,617,469 shares valued at approximately $18.67 million.
• KalVista's stock experienced a 1.4% decline, with a recent trading price of $15.39, following a disappointing earnings report that missed analysts' estimates.
• Several analysts have raised their price targets for KalVista, with HC Wainwright increasing its target from $20 to $27, indicating a positive outlook and a "buy" rating.

Woodline Partners LP grew its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 25.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,617,469 shares of the specialty pharmaceutical company's stock after acquiring an additional 329,068 shares during the period. Woodline Partners LP owned about 3.25% of KalVista Pharmaceuticals worth $18,666,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in KalVista Pharmaceuticals by 3.4% during the 1st quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock worth $611,000 after acquiring an additional 1,762 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of KalVista Pharmaceuticals by 567.3% in the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after buying an additional 3,767 shares during the period. Bank of America Corp DE boosted its holdings in shares of KalVista Pharmaceuticals by 108.8% in the 4th quarter. Bank of America Corp DE now owns 110,050 shares of the specialty pharmaceutical company's stock valued at $932,000 after buying an additional 57,356 shares during the period. ProShare Advisors LLC acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at about $101,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at about $452,000.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,942 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $38,893.24. Following the completion of the transaction, the insider directly owned 119,841 shares of the company's stock, valued at $1,584,298.02. The trade was a 2.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 32,979 shares of the business's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the transaction, the chief executive officer directly owned 369,595 shares of the company's stock, valued at $5,798,945.55. The trade was a 8.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 59,835 shares of company stock valued at $892,350 over the last three months. 4.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on KALV. HC Wainwright lifted their price target on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Leerink Partners lifted their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday, July 7th. Finally, JMP Securities lifted their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. According to data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $26.29.

KalVista Pharmaceuticals Stock Down 1.4%

KalVista Pharmaceuticals stock opened at $15.39 on Thursday. The firm has a 50-day moving average price of $14.04 and a two-hundred day moving average price of $12.74. The firm has a market capitalization of $774.73 million, a price-to-earnings ratio of -4.17 and a beta of -0.10. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $16.33.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter in the previous year, the business earned ($1.07) EPS. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.